Viscosupplementation Market Size, Share, Opportunities, And Trends By Dosage (Single Injection, Three Injection, Five Injection), By Application (Knee Osteoarthritis, Hip Osteoarthritis, Shoulder Osteoarthritis, Others), By End-user (Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics), And By Geography - Forecasts From 2025 To 2030

Description

The viscosupplementation market is anticipated to grow significantly over the forecast period.

Key Market Highlights:

• The main factor propelling the market's expansion is the increasing incidence of osteoarthritis.
• The need for minimally invasive joint pain treatments is fueled by the growing geriatric population.
• Convenience is increased by the growing use of next-generation and single-injection HA products.
• Treatment accuracy is increased by using image-guided injection techniques more often.
• In developed markets, uptake is supported by favorable reimbursement policies.

One typical medical method for treating osteoarthritis, especially in the knee joint, is viscosupplementation. To increase lubrication and lessen discomfort and inflammation, hyaluronic acid (HA), a viscous fluid, is injected into the joint area. The synovial fluid contains hyaluronic acid, a naturally occurring chemical that lubricates and cushions joints. Increased friction and discomfort result from the natural HA in the joint being thinner and less effective due to osteoarthritis. The goal of viscosupplementation is to improve joint function and lessen discomfort by restoring the synovial fluid's viscosity and flexibility. This treatment is regarded as a non-surgical approach to treating osteoarthritis symptoms and is usually administered as a series of injections spread out over a few weeks.

Osteoarthritis is becoming more common, the need for less intrusive treatments is growing, and the aging population is driving major growth in the viscosupplementation industry. Viscosupplements are injected into joints to lubricate them and reduce pain related to osteoarthritis. They are made of hyaluronic acid. The market is developing due to technological developments in viscosupplementation techniques and growing use in knee, hip, and shoulder joints. The market is expected to increase at a rapid rate, due in part to advantageous reimbursement policies and rising public awareness of the advantages of viscosupplementation. Generally, as the demand for efficient osteoarthritis management options rises, the viscosupplementation market is expected to continue growing.  

Key players working in the market include Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Chugai Pharmaceuticals Co., Ltd, Ferring Pharmaceuticals, OrthogenRx Inc., and Wellchem Pharmaceuticals Pte Ltd.

Viscosupplementation Market Trends

• The Increasing Prevalence of Osteoarthritis

The prevalence of cardiac arrhythmias is increasing worldwide, owing to factors such as aging populations, sedentary lifestyles, and rising rates of cardiovascular disease. Cardiac arrhythmias refer to a variety of diseases, including atrial fibrillation, ventricular tachycardia, and bradyarrhythmias, all of which can have a major impact on patient health and quality of life. As the prevalence of risk factors such as obesity, hypertension, and diabetes rises, so does the impact of cardiac arrhythmias on global healthcare systems. This development highlights the growing need for effective diagnostic and therapeutic options to address the rising prevalence of cardiac arrhythmias while lowering associated morbidity and mortality rates.

According to NCBI in 2023, the most prevalent type of arthritis identified is knee osteoarthritis, and as life expectancy and obesity increase, so too will the incidence of this condition. Roughly 10% of men and 13% of women 60 years of age and older have symptomatic osteoarthritis in their knees, according to various sources. The frequency increases to 40% among people over the age of 70. Men are also less likely than women to have osteoarthritis in their knees. Remarkably, not all individuals exhibiting radiographic signs of osteoarthritis in the knee will experience symptoms. According to one study, only 15% of patients with knee OA identified on radiographs also had symptoms. When age is not considered, the annual incidence of symptomatic knee osteoarthritis is about 240 cases per 100,000 persons.

Viscosupplementation Market Dynamics

• Market Drivers

Technological Advancement in Viscosupplementation is Expected to Boost the Market

Treatment choices for patients with osteoarthritis have been changed by technological breakthroughs in the viscosupplementation business. The safety and efficacy of viscosupplementation therapy have been greatly increased by innovations like better delivery devices, optimized formulations, and better injection techniques. Modern biomaterials and cross-linking methods guarantee the long-term strength and effectiveness of materials injected into joints. In addition, the advancement of ultrasound and fluoroscopy-guided injection techniques allows for accurate administration, improving the results of treatment. The incorporation of digital health technologies enables the implementation of customized treatment regimens and remote monitoring. These developments broaden the usefulness and acceptability of viscosupplementation therapy, which not only enhances patient experience but also propels market growth.

According to NCBI, one prevalent hallmark of inflammatory OA is synovitis, which has been detected in many patients at different stages of the illness by technological advancements in imaging technologies such as MRI and ultrasound. Numerous factors, such as abnormal mechanical pressures, metabolic syndrome, aging, and pieces of extracellular matrix (ECM) or crystals in the cartilage, may cause the release of these mediators from different types of responsive joint tissue cells. Numerous new review studies discuss how the innate immune system's cells and elements are the primary causes of the inflammatory processes associated with OA. Although glucocorticoids and non-steroidal anti-inflammatory medications (NSAIDs) are frequently used to treat osteoarthritis (OA), their efficacy is limited, and their long-term use can have substantial side effects.

Market Restraints

• High Treatment Costs and Limited Affordability

Even at the higher end of the viscosupplement type, a single injection will likely be more expensive than the other pain management options like NSAIDs, corticosteroid injection, or physical therapy. This cost burden is even more significant in developing economies and countries where out-of-pocket spending is the dominant form of spending in the health sector. In many countries, poor insurance coverage or partial reimbursement limits patient access to the viscosupplement option, especially in cases of needing multiple injections.  

• Availability of Alternative Treatments and Competition from Other Therapeutic Approaches

Viscosupplementation, a treatment for osteoarthritis, offers pain reduction and improved joint function despite its competition with oral drugs, physical therapy, and surgical procedures. However, patient variability in efficiency raises questions about its long-term effects and usefulness. Access to and acceptance of viscosupplementation may be limited by uneven insurance coverage and payment regulations. Further research, instruction, and cooperation are needed to maximize its application.

Market Opportunities

• The Aging Population

The market for viscosupplementation is significantly influenced by the aging population since osteoarthritis, which is characterized by stiffness and pain in the joints, is more common in older people. Osteoarthritis cases are becoming more common due to the world's demographic shift toward an aging population, especially in affluent nations. The natural lubricant in people's joints decreases with age, causing discomfort and limited movement. By adding more synovial fluid to joints, viscosupplementation offers an efficient therapeutic approach that reduces discomfort and enhances joint function. Thus, the market for viscosupplementation is expanding because of the aging population's growing need.

Additionally, WHO 2023 reported that osteoarthritis affected around 528 million individuals globally in 2019, a 113% rise since 1990. Over 55-year-olds make up about 73% of those with osteoarthritis, and 60% of those affected are female. The knee is the most affected joint, with a prevalence of 365 million, followed by the hip and the hand. Rehabilitation could be beneficial for 344 million individuals who suffer from mild to severe osteoarthritis. Globally, osteoarthritis prevalence is predicted to rise because of aging populations, rising rates of obesity, and an increase in injuries. Osteoarthritis is an inevitable side effect of becoming older.

Viscosupplementation Market Segmentation Analysis

• By Dosage

Based on dosage, the market is classified into single injection, three injection, and five injection.

The five-injection segment is the fastest-growing dosage form used in viscosupplementation, owing to its accepted clinical efficacy, and patients and physicians being comfortable with the number of injections. Two-injection and three-injection forms are predominant in the market, based on their convenience and ease of use, whereas the five-injection regimen demonstrates a more gradual release and sustained effects of hyaluronic acid within the joint (for lubrication, cushioning, or pain relief). Physicians generally prefer a five-injection regimen for moderate to severe knee osteoarthritis, as they can monitor the patient's progress over five appointments and expect a comparable outcome for each visit.

Evidence suggests that five-injection therapy can expect greater improvements in joint functioning, mobility, and inflammation reduction, compared to shorter or single-dose regimens. This can be the preferred option if the patient is interested in durable relief over ease of delivery. Established reimbursement practices for multi-injection therapy in many developed care markets encourage taking up therapy in practice. There are single and multi-visit options that focus on overnight treatment (and cost), but with five injection therapy, there is evidence, physician support, and higher satisfaction. Thus, we foresee a substantial growth in the five-dose injection therapy with aging populations who are experiencing degeneration of joints.  

Viscosupplementation Market Regional Analysis

• By region, the market is segmented into North America, South America, the Middle East and Africa, and Asia-Pacific.

North America

North America is the largest market for viscosupplementation because of the prevalent factors, including a high incidence and prevalence of osteoarthritis, a strong health care system, and the increasing acceptance of minimally invasive pain management options. The U.S. is a significant revenue generator due to its large aging population, high osteoarthritis diagnosis rates, and reimbursement policies that promote the use of multi-injection regimens in patients with osteoarthritis. The presence of several prominent market players, along with the continuous investment into R&D and the availability of next-generation single-injection products that are FDA approved, also drives growth in the region. The increasing use of outpatient and ambulatory care services, and increased awareness of viscosupplementation as an alternative to joint replacement surgery, also drives adoption. Canada also continues to support market growth with government initiatives to address the disability burden associated with osteoarthritis.

Europe

Europe represents a considerable portion of the viscosupplementation market, with primary markets including Germany, France, Italy, and the UK. Europe is aided by an aging population, established reimbursement systems, and a strong acceptance of hyaluronic acid treatments by orthopedic clinics. Germany is the largest viscosupplementation market in Europe, due to innovative facilities and increased willingness among patients and physicians to accept a treatment protocol that does not involve surgery. Furthermore, physicians in both France and Italy have adopted viscosupplementation due to their confidence in multi-injection regimes for hyaluronic acid therapies. However, growth in the viscosupplementation market has been limited by challenges from a debate from European medical associations regarding the actual long-term efficacy of viscosupplementation treatments compared to other, more acceptable treatments. Ongoing evidence for product innovations, availability of image-guided injection procedures, and patients' desire to delay knee replacement surgery are factors that continue to support the viscosupplementation market across Europe.

Asia-Pacific

In the Asia-Pacific area, viscosupplementation, a therapy that involves injecting hyaluronic acid into joints to relieve osteoarthritis pain, has grown rapidly. This growth has been driven by elements including an aging population, an increase in osteoarthritis cases, and growing knowledge of non-surgical treatment alternatives. Because of their substantial older populations and sophisticated healthcare systems, nations like China, Japan, and South Korea have seen a strong uptake. Furthermore, the spike in demand has been attributed to both technological developments and pharmaceutical corporations' aggressive marketing campaigns. The market for viscosupplementation in the Asia-Pacific region is expected to rise further due to changing patient preferences and increased accessibility to healthcare services.

South America

The viscosupplementation market in South America is growing gradually, with Brazil and Argentina leading the way. The demand for less intrusive ways to treat osteoarthritis is being propelled by the increasing prevalence of osteoarthritis associated with sedentary lifestyles, obesity, and aging. Both Brazil, with its large patient population and evolving private healthcare sector, and Argentina, with its increasing adoption of viscosupplementation among physicians to avoid surgical interventions, are emergent opportunities for growth. Challenges in the region exist with limited reimbursements, uneven healthcare structure, and reliance on imported products, increasing the costs of treatment. Nevertheless, educational campaigns and increased healthcare spending by the growing middle class are assisting in market penetration.

The Middle East and Africa

The viscosupplementation market in the MEA is still in its infancy stage, but has significant growth potential. The Gulf Cooperation Council (GCC) countries, particularly Saudi Arabia and the UAE, are seeing increased adoption rates due to rising healthcare spending, modernization of healthcare facilities, and increased burden of osteoarthritis associated with the obesity rates and aging populations. Conversely, Africa is limited by a lack of access, low levels of awareness, weak healthcare infrastructure, and affordability issues that continue to hinder adoption. However, continued gradual entry of international companies, government healthcare initiatives, and increased demand for advanced therapies in urban areas will create opportunities for viscosupplementation in the region. 

Viscosupplementation Market Competitive Landscape

The market for viscosupplementation is marked by the number of established companies such as Sanofi S.A., Zimmer Biomet Holdings Inc., Bioventus LLC, Anika Therapeutics Inc., Fidia Farmaceutici S.p.A., Chugai Pharmaceuticals Co., Ltd, Ferring Pharmaceuticals, OrthogenRx Inc., and Wellchem Pharmaceuticals Pte Ltd. These companies are focused on expanding their product portfolios by funding new hyaluronic acid formulations entering the market, developing collaborative initiatives, and expanding their worldwide distribution networks to meet the increasing demand for osteoarthritis management.

List of Key Company Profiled

• Sanofi S.A.
• Zimmer Biomet Holdings Inc.
• Bioventus LLC
• Anika Therapeutics Inc.
• Fidia Farmaceutici S.p.A.
• Chugai Pharmaceuticals Co., Ltd
• Ferring Pharmaceuticals
• OrthogenRx Inc.
• Wellchem Pharmaceuticals Pte Ltd.  

Viscosupplementation Market Key Developments

• Product Launch: In April 2025, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, announced that it had received approval for Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis. Tremfya is the first and only IL-23 inhibitor to show statistically significant improvements in both signs and symptoms of active psoriatic arthritis and the progression of structural damage. Tremfya's approval is based on clinical trial results, with patients in the Tremfya group showing improvement in joint symptoms, skin lesions, and patient-reported outcomes.   
• Product Launch: In February 2024, IBSA UK, the UK branch of IBSA Group, which is based in Switzerland, introduced its latest SINOVIAL product range to the UK for the treatment of osteoarthritis. The SINOVIAL product range consists of a proprietary formulation using NAHYCO technology, which combines both high- and low-molecular weight hyaluronic acid to enhance joint lubrication and support healthy joint function.       
• Product Launch: In May 2022, Fidia Farmaceutici S.p.A. launched its cutting-edge range in Spain in May 2022, utilizing hyaluronic acid's capacity for regeneration. During a scientific seminar on its novel ACP (Auto-Crosslinked Polymer) technology, Fidia Farmaceutici S.p.A. showcased its Aesthetic Care portfolio at the 20th Aesthetic & Anti-aging Medicine World Congress 2022 (AMWC) in Monte Carlo. In Spain, the business has introduced the whole Hyal System and Hy-Tissue product line. This has aided the business in showcasing its hyaluronic acid research.
• Collaboration: In April 2022, to develop and commercialize TissueGene-C low dose (TG-C LD), a non-surgical experimental therapy provided as a single intra-articular injection, to treat knee osteoarthritis, Juniper Biologics and Kolon Life Sciences inked a licensing agreement in April 2022. As part of the licensing agreement, Juniper will research and promote gene therapy to hospitals and physicians throughout Africa, the Middle East, and Asia-Pacific.

Segmentation

• By Dosage
  • Single Injection
  • Three Injection
  • Five Injection
• By Application
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Shoulder Osteoarthritis
  • Others
• By End-user
  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopedic Clinics
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

Table Of Contents

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. VISCOSUPPLEMENTATION MARKET BY DOSAGE

5.1. Introduction

5.2. Single Injection

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.3. Three Injection

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.4. Five Injection 

5.4.1. Market Opportunities and Trends

5.4.2. Growth Prospects

6. VISCOSUPPLEMENTATION MARKET BY APPLICATION

6.1. Introduction

6.2. Knee Osteoarthritis

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.3. Hip Osteoarthritis

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.4. Shoulder Osteoarthritis

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.5. Others

6.5.1. Market Opportunities and Trends

6.5.2. Growth Prospects

7. VISCOSUPPLEMENTATION MARKET BY END-USER

7.1. Introduction

7.2. Hospitals

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.3. Ambulatory Surgical Centers

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.4. Orthopedic Clinics

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

8. VISCOSUPPLEMENTATION MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Dosage

8.2.2. By Application

8.2.3. By End User

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Opportunities and Trends

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Opportunities and Trends

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Opportunities and Trends

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Dosage

8.3.2. By Application

8.3.3. By End User

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Opportunities and Trends

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Opportunities and Trends

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Opportunities and Trends

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Dosage

8.4.2. By Application

8.4.3. By End User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.1.1. Market Opportunities and Trends

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Opportunities and Trends

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Opportunities and Trends

8.4.4.3.2. Growth Prospects

8.4.4.4. Italy

8.4.4.4.1. Market Opportunities and Trends

8.4.4.4.2. Growth Prospects

8.4.4.5. Spain

8.4.4.5.1. Market Opportunities and Trends

8.4.4.5.2. Growth Prospects

8.4.4.6. Others

8.4.4.6.1. Market Opportunities and Trends

8.4.4.6.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Dosage

8.5.2. By Application

8.5.3. By End User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Opportunities and Trends

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Opportunities and Trends

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Opportunities and Trends

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Dosage

8.6.2. By Application

8.6.3. By End User

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Opportunities and Trends

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Opportunities and Trends

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Opportunities and Trends

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Opportunities and Trends

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Opportunities and Trends

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Opportunities and Trends

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Opportunities and Trends

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Opportunities and Trends

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Sanofi S.A.

10.2. Zimmer Biomet Holdings Inc.

10.3. Bioventus LLC

10.4. Anika Therapeutics Inc.

10.5. Fidia Farmaceutici S.p.A.

10.6. Chugai Pharmaceuticals Co., Ltd

10.7. Ferring Pharmaceuticals

10.8. OrthogenRx Inc. 

10.9. Wellchem Pharmaceuticals Pte Ltd. 

Companies Profiled

Sanofi S.A.

Zimmer Biomet Holdings Inc.

Bioventus LLC

Anika Therapeutics Inc.

Fidia Farmaceutici S.p.A.

Chugai Pharmaceuticals Co., Ltd

Ferring Pharmaceuticals

OrthogenRx Inc. 

Wellchem Pharmaceuticals Pte Ltd. 

Related Reports